Order Article Reprints

Narukawa T, Yasuda S, Horinaka M, Taniguchi K, Tsujikawa T, Morita M, Ukimura O, Sakai T. The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma. Cancers. 2024; 16(23):4058. https://doi.org/10.3390/cancers16234058

Narukawa, Tsukasa, Shusuke Yasuda, Mano Horinaka, Keiko Taniguchi, Takahiro Tsujikawa, Mie Morita, Osamu Ukimura, and Toshiyuki Sakai. 2024. "The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma" Cancers 16, no. 23: 4058. https://doi.org/10.3390/cancers16234058

Narukawa, T., Yasuda, S., Horinaka, M., Taniguchi, K., Tsujikawa, T., Morita, M., Ukimura, O., & Sakai, T. (2024). The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma. Cancers, 16(23), 4058. https://doi.org/10.3390/cancers16234058